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Introduction: Stem cell therapy with bone marrow-derived mononuclear cells (BMMCs) is an option for improving
joint function in osteonecrosis of the femoral head (ONFH). Bone marrow-derived mesenchymal stromal cell (MSC)
numbers and their osteogenic differentiation are decreased in patients with ONFH. However, whether this decrease
also extends to the early stages of ONFH in sickle cell disease (SCD) is still unclear.
Methods: We conducted a phase I/II, non-controlled study to determine efficacy and safety of BMMC implantation
using a minimally invasive technique in SCD patients with ONFH. Eighty-nine patients were recruited and followed
up for 60 months after surgery. Clinical and radiographic findings were assessed, and data were completed by
in vitro analysis.
Results: At the final follow-up (60 months) there was a significant improvement in clinical joint symptoms and pain
relief as measured by the Harris Hip Score (P = 0.0005). In addition, after the BMMC implantation procedure,
radiographic assessment showed disease stabilization and only 3.7 % of the treated patients did not achieve a
satisfactory clinical result. The amount of fibroblast colony-forming units was 28.2 ± 13.9 per 1 million BMMCs after
concentration. Flow cytometry analysis showed a significantly higher number of hematopoietic stem/endothelial
progenitor cell markers in concentrated BMMCs when compared with bone marrow aspirate, indicating an
enrichment of these cell types. Isolated MSCs from SCD patients with pre-collapse ONFH maintained the replicative
capacity without significant loss of their specific biomolecular characteristics, multi-differentiation potential, and
osteogenic differentiation activities. Cytokines and growth factors (interleukin-8, transforming growth factor-beta,
stromal cell-derived factor-1alpha and vascular endothelial growth factor) that mediate endogenous bone
regeneration were also produced by expanded MSCs from SCD patients.
Conclusion: The autologous BMMC implantation with a minimally invasive technique resulted in significant pain
relief and halted the progression of early stages of ONFH in SCD patients. MSCs from SCD patients display
biological properties that may add to the efficiency of surgical treatment in ONFH. In summary, our results indicate
that infusion of BMMCs enriched with stem/progenitor cells is a safe and effective treatment for the early stages of
ONFH in SCD patients.
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Sickle cell disease (SCD) is the most common inherited
blood disease, with a worldwide distribution. In Brazil,
the prevalence of hemoglobin S (HbS) carriers varies
from 6 % to 15.7 % among different population groups
[1]. The highest frequency of abnormal hemoglobin and
the rate of race admixture, mainly of African descendent,
means the presence of hemoglobinopathies is considered
a public health problem in northeast Brazil [2, 3].
Osteonecrosis of the femoral head (ONFH) is a de-
bilitating and severe complication of SCD and its treat-
ment is still a big challenge. Depending upon the
particular genotype and severity of the SCD, the preva-
lence of ONFH ranges from 3 to 50 % among SCD pa-
tients [4, 5].
Osteonecrosis can be viewed as a vascular and bone
disease with altered bone remodeling. The combination
of vascular and bone pathologies contributes to the de-
velopment of osteonecrosis, which leads to inadequate
bone repair that advances to subchondral fracture [6, 7].
Patients with SCD experience both large and small ves-
sel occlusions leading to end-organ damage and compli-
cations such as ONFH. These vascular occlusion events
result from various processes including hypoxia-induced
erythrocyte sickling, along with extravascular compres-
sion of the intra-osseous blood supply resulting in an
imbalance between osteoblast formation and necrosis,
which culminates in femoral head infarction [8]. If left
untreated, ONFH has a high likelihood of progression to
secondary arthrosis in up to 86 % of cases [7, 9]. Once
collapse occurs, total arthroplasty is a possible treat-
ment, but its high rates of infection, medical and surgical
complications, lead to overall failure rates ranging from
5 % to 63 % in SCD patients [4, 10]. Since ONFH most
frequently occurs in young patients, a treatment preserv-
ing the femoral head instead of replacing it is preferable
whenever possible.
Treatment of early-stage ONFH with autologous infu-
sion of concentrated bone marrow-derived mononuclear
cells (BMMC) into the necrotic lesion has been shown
to be effective and safe [11, 12]. Promising results were
achieved in a majority of patients when the cell therapy
was applied at early stages before the collapse, to pre-
serve the structural integrity of the subchondral plate
[11, 13]. BMMCs contain bone marrow-derived mesen-
chymal stromal cells (MSCs) with osteogenic and chon-
drogenic capacity, as well as endothelial progenitor cells
(EPCs) which are able to promote formation of new
blood vessels and improve tissue regeneration. Mao and
coworkers demonstrated that targeted delivery of autolo-
gous BMMCs enriched with MSCs could relieve symp-
toms, improve hip function and delay the progression of
ONFH [14]. Similarly, in an experimental animal model
of ONFH, Yan et al. [13] demonstrated that transplantedMSCs could differentiate into osteoblasts in the osteo-
necrotic region of ONFH, and secrete angiogenic factors
resulting in increased angiogenesis, which in turn could
contribute to the bone repair. Therefore, both the in-
creased supply of vasculogenic and bone-forming progeni-
tor cells [15], their homing abilities to injury sites [16, 17]
and their paracrine release of a variety of growth factors
[18] make the application of BMMCs with enriched stem/
progenitor cell content an ideal cell-based approach to
prevent fracture and collapse by restoring the architecture
of the femoral head in early-stage osteonecrosis.
Among the multiple attributes of stem/progenitor cells
in BMMCs, the osteogenic activity and replicative capacity
of MSC are thought to play an important role in a suc-
cessful therapeutic outcome in osteonecrosis. However,
several reports recently suggested that MSC numbers and
osteogenic differentiation abilities were impaired in pa-
tients with corticosteroid-induced and alcohol-induced
ONFH [19–21]. In addition, several reports have indicated
that BMMC isolation-yield and MSC replicative capacities
are reduced in non-traumatic ONFH [22, 23]. A com-
parative analysis of the osteogenic activity and growth
potential of MSCs in patients with ONFH has shown
differences according to the risk factors [21], but
whether this impairment also extends to stem/progeni-
tor cells from the early stages of ONFH related to SCD
is still unclear.
The 1-year results of the observational pilot study on
the efficacy and safety of BMMC implantation suggested
that cell-based therapy could improve joint symptoms
and delay disease progression in our population [24].
However, these results needed to be confirmed by the 5-
year follow-up to emphasize their clinical relevance. We
will present here the 5-year results to investigate the effi-
cacy and safety of autologous BMMC implantation com-
bined with a minimally invasive decompression technique
as a treatment for early stage ONFH in SCD patients. Our
clinical and radiographical findings were complemented
with promising in-vitro data. Because there is a paucity
of recent MSC reports in patients who have sickle cell
hemoglobinopathy, we undertook this study to evaluate
whether the biological properties of human MSCs sup-




This single center prospective study was conducted in
the university-affiliated Professor Edgard Santos Hospital
(HUPES, UFBA) in Salvador (BA), Brazil. The Commit-
tee of Ethics in Research of the Climério de Oliveira Ma-
ternity and the National Committee of Ethics in
Research (CONEP) approved the protocol of the present
study under the authorization of the Ministry of Public
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25000.039812/2005–99). Written informed consent was
obtained from every patient before enrollment in the
study.
Participant selection
From 2006 to 2013, 89 patients were submitted to im-
plants of BMMCs according to the technique described
by Hernigou and Beaujean [11]. Inclusion criteria for
SCD patients with early stages (pre-collapse) of ONFH
were those of conventional core decompression surgery
(that is, radiological diagnosis of ONFH according to
Ficat stage 0, I, IIA and IIB or Steinberg classification A,
B or C; see Additional file 1) [25, 26], and scoring at
least 20 points on the pain and daily life activities ques-
tionnaire. The exclusion criteria were patients under 18
years of age, those with Ficat stage III and Steinberg’s C
(or more) ONFH, current and previous bone infection at
the limb affected by necrosis, acute recurrent painful cri-
ses, immunosuppressive drug therapy, a history of previ-
ous surgery on the same injured limb, prior systemic
corticosteroid treatment, pregnancy, presence of neo-
plastic disease or any other clinical concurrent condition
other than SCD that predisposed them to the develop-
ment of osteonecrosis of the femoral head (e.g., a history
of chronic systemic steroid use or alcoholism) or contra-
indicating the procedure.
The hematology analyses of patients were carried out in
an automatic Coulter T 890 device (Beckman Coulter, Inc.,
Brea, CA, USA). SCD diagnosis and the hemoglobin ana-
lyses were confirmed by cellulose acetate electrophoresis at
alkaline pH [27]. A total of 41 men and 48 women were in-
cluded in this study. The mean age of patients at the time
of treatment was 33 years (18 to 55 years). Among them,
61.8 % were HbSC, sickle-hemoglobin C disease patients
and 38.2 % were HbSS, sickle cell anemia patients.
Clinical and radiographic evaluation
Two experienced orthopedic surgeons assessed the clin-
ical outcomes of all patients. Patients were evaluated
preoperatively, and 3, 6, 12, 24, 36, 48 and 60 months
postoperatively, or whenever necessary. Patient’s pain
(44 points), joint function (47 points), joint range of mo-
tion (5 points), and deformities (4 points) were recorded
according to Harris Hip Score (HHS) system as 0 to 100
points. HHS was obtained preoperatively and at each
follow-up visit. Outcomes were graded as excellent when
the HHS was greater than 90 points, good when it was
between 80 and 89 points, fair when it was between 70
and 79 points, and poor when it was less than 70 points,
according to previous reports [28, 29]. Each hip of patients
suffering from bilateral hip involvement was examined
separately. Complications of the treatment were registered
at each follow-up. Patients that developed a superficialskin or wound infection were treated successfully non-
operatively with antibiotics. Efficacy of the procedure was
evaluated via: (1) improvement in pain and range of mo-
tion - HHS was compared to the score before surgery; (2)
radiological progression; and (3) the need for further sur-
gery or hip replacement.
ONFH diagnosis was determined by X-ray image exam-
ination at the antero-posterior and lateral planes. When
SCD patients had moderate to severe pain localized in the
hip or inguinal area, and physical examination showed
limitation of movement of the affected hip while X-ray
showed no changes, the diagnosis of ONFH was made by
magnetic resonance imaging (MRI) at the onset of treat-
ment. Radiological progression was decided according to
the development of the Ficat stage and Steinberg classifi-
cation aiming to determine the following characteristics:
presence of femoral head collapse; presence of a sclerosis
range on femoral head; crescent sign; double signal at T2
on MRI; cyst or sclerosis on femoral head; hip pain at
motion; low-intensity focus on T1.
Bone marrow cell collection and concentration
A total of 120 mL bone marrow aspirate (BMA) was ob-
tained by puncture and aspiration of the posterior iliac
crest of patients under general anesthesia. The marrow
was aspirated in small fractions at a time (10 mL hepa-
rinized plastic syringe) to reduce the degree of dilution
by peripheral blood and to maximize the number of pro-
genitors in the graft site [30]. BMMCs were concentrated
in the SEPAX cell separator (Biosafe, Eysins, Switzerland)
in accordance with the manufacturer’s recommendations.
After centrifugation, a final volume (~40 mL) of BMMCs
in suspension with 5 % human serum albumin was har-
vested and placed in syringes for re-injection during the
same operation. A small fraction of the BMA and BMMCs
were separated for flow cytometry, cell viability and
microbiological assays.
BMMC grafting
The concentrated BMMC was injected through a percu-
taneous approach using a 3-mm diameter trocar (trocar
of Mazabraud, Collin, France) in the center of the osteo-
necrotic area. The procedure was previously planned
using nuclear magnetic resonance images, and the nee-
dle position at the femoral head area was monitored by
fluoroscopy. Each patient received the BMMC infusion
through a single injection puncture. A small local blood
tampon avoided leakage of the infused BMMC fraction.
Clonal BMMC assays
Colony-forming unit fibroblast (CFU-F) assays were per-
formed to determine the number of mesenchymal progen-
itors in BMMC samples, as described previously [31].
Briefly, single cell suspensions of BMMCs were cultivated
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Eagle’s medium (DMEM) low glucose (Sigma, St. Louis,
MO, USA), supplemented with 20 % fetal bovine serum
(Cultilab, Campinas, Brazil), 100 U/mL penicillin and 100
μg/mL streptomycin (Invitrogen, Grand Island, NY, USA)
and incubated in 5 % CO2 at 37 °C. Medium was renewed
every third day. After 10 days, the non-adherent cells were
removed by washing with phosphate-buffered saline and
the remaining adherent cells were fixed in 4 % buffered
formalin for 10 minutes. To detect CFU-F, the cells were
stained with Crystal Violet solution. The cultures were
scored for clusters (20–50 cells/aggregate) and colonies
(>50 cells) at 10× magnification microscopy. To determine
the colony-forming unit osteoblast (CFU-O) potential of
BMMCs, cells were cultivated in basal media containing
10 nM dexamethasone (Sigma), 5 mM sodium β-
glycerophosphate (Sigma), and 50 mg/mL ascorbic
acid-2-phosphate (Sigma) and plated as described [32].
After 21–24 days in culture, CFU-O were fixed in 4 %
buffered formalin for 10 minutes and stained with Ali-
zarin S for mineralization (see below).
Immunophenotyping
BMMCs and BMA were analyzed for the expression of
cell-surface antigens with direct three-color analysis
using fluorescein isothiocyanate (FITC)-conjugated, phyco-
erythrin (PE)-conjugated and peridinin chlorophyll protein
complex (PerCP)-conjugated monoclonal antibodies as
previously reported [33, 34]. The following antibodies
were used for analysis: immunoglobulin G1 control PE
(eBioscience, San Diego, CA, USA), immunoglobulin G1
control PerCP (Becton Dickinson, San Jose, CA, USA),
immunoglobulin G1 control FITC (BD Bioscience, Frank-
lin Lakes, NJ, USA), anti-CD34-FITC (BD Bioscience),
anti-CD34-PerCP (Becton Dickinson), anti-KDR-PE (R&D
Systems, Minneapolis, MN, USA), anti CD45-PerCP (BD
Bioscience), and anti-CD133–PE (Miltenyi Biotec,
Bergisch Gladbach, Germany). The quantification of total
mononuclear cells in BMMCs and BMA was determined
by Turk’s solution. For FACS analysis, 5 × 105 events were
acquired and scored with a FACSCalibur analyzer (Becton
Dickinson). Data were processed using the Macintosh
CELLQuest software program (Becton Dickinson).
BMMC viability and quality control
The viability of infused cells, as determined by Trypan
blue exclusion, was above 95 %. The study of the pres-
ence of potential microbiologic contaminants, monitored
by blood culture and traditional microbiologic tests,
showed negative results.
Isolation and culture of primary human MSCs
BMMCs were plated at a density of 1.6 × 105 mononu-
cleated cells/cm2 in DMEM low-glucose as describedabove. After 4–5 days of culture, the non-adherent cells
were discarded and the medium was refreshed twice a
week. On reaching 90 % confluence, the cells were sub-
cultured using 0.05 % trypsin–0.02 % EDTA at a 1:3 ra-
tio. MSCs were used up to passage 6 for all studies.
Immunophenotypic characterization of MSCs
The expanded MSC population at third passage in cell
culture were characterized by morphology (spindle-
shaped cells) and by immunophenotypic analysis for the
expression of the following membrane markers: mouse
anti-human CD14-PE (clone 61D3), CD29-FITC (clone
TS2/16), CD90-FITC (clone eBIO5E10) and CD105-PE
(clone SN6) (from eBioscience), CD31-FITC (clone
WM59), CD34-FITC (clone 8G12), CD45-PerCP-Cy5.5
(clone MOPC-21) and CD146-PE (clone P1H12) (from
BD Biosciences, San Jose, CA, USA). Detection of osteo-
calcin in MSC culture by flow cytometry was performed
with mouse anti-human PE-conjugated monoclonal anti-
body (R&D system) or isotype control antibody accord-
ing to the manufacturer’s protocol.
Osteogenic differentiation of MSCs and matrix
quantification
For osteogenic differentiation, 5.0 × 104 MSCs were
plated in a 24-well plate in triplicate. Osteogenic differ-
entiation was induced by culturing confluent MSCs in
DMEM basic medium (4 mmol/L L-glutamine/penicil-
lin/streptomycin, 10 % fetal bovine serum) supplemented
with 100 nmol/L dexamethasone (Sigma), 5 mM sodium
β-glycerophosphate (Sigma), and 50 μg/mL ascorbic acid
2-phosphate (Sigma) for 21 days, with media change
every 3–4 days. After differentiation, cells were fixed for
10 minutes with 70 % ice-cold ethanol and subsequently
stained with Alizarin Red (Sigma; 1 % Alizarin Red in
distilled water, pH 4.2) to indicate calcium deposition
and mineralized nodules within the extracellular matrix
[21]. Morphological evaluation of cells was performed using
a DM IL LED inverted microscope (Leica, Wetzlar,
Germany) coupled to a digital camera for imaging capture.
Quantitative analysis of the amount of Alizarin staining
was performed with Fiji (NIH, Bethesda, Maryland, USA).
Five fields were selected and the newly formed mineral-
ized tissue area in each field was calculated and shown as
a percentage of total tissue area.
Adipogenic differentiation of MSCs
MSCs were seeded into 24-well tissue-culture plates at a
density of 5.0 × 104 cells/well. Adipogenic differentiation
was induced in confluent MSC incubated with DMEM
basic medium supplemented with 10 μg/mL insulin, 500
μmol/L 3-isobutyl-1-methylxanthine, 100 μmol/L indo-
methacin and 1 μmol/L dexamethasone. After 3 weeks
of adipogenic stimulation, cells were fixed with 4 %
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water, and incubated with 0.5 % oil red O in isopropanol
for 20 minutes at room temperature. After staining, cells
were washed with 60 % isopropanol and rinsed with
sterile water, before observing under the microscope for
imaging [21].
Chondrogenic differentiation
Chondrogenic differentiation was carried out using
micromass cell cultures under chondrocyte differenti-
ation medium (Invitrogen) for 30 days. One million
MSCs were pelleted at 300 g and chondrocyte differenti-
ation medium was added without disturbing the pellet.
Media was changed every 48 hours. After differentiation,
cells were fixed with 4 % paraformaldehyde and embed-
ded in paraffin. Deparaffinized 5 μm sections were stained
for proteoglycans using 3 % Alcian blue. After staining,
sections were rinsed with distilled water, air dried at room
temperature, immersed in xylene, and mounted for mi-
croscopy. Images were taken with a Nikon Ti Eclipse
microscope (Tokyo, Japan).
Quantitative RT-PCR
To determine the relative expression levels of the osteo-
genic markers, 3.0 × 105 MSCs were seeded onto 25-
cm2 flasks and maintained in control conditions or
osteogenic differentiation medium. After 7 days, cells
were washed with ice-cold phosphate-buffered saline,
and total mRNA was isolated using silica columns from
the RNeasy® mini-kit (Qiagen, Hilden, Germany), ac-
cording to the manufacturer’s protocol. The mRNA con-
centration was determined by absorbance at 260 nm and
the purity of the preparations was evaluated by the
A260nm/A280nm ratio using a Nanodrop ND-1000
spectophotometer (NanoDrop Technologies, Rockland,
DE, USA). cDNA was synthesized from 1 μg total RNA
using Superscript II reverse transcriptase (Invitrogen),
followed by RNA digestion with RNase H (Invitrogen).
cDNA purity was confirmed by PCR for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH).
Quantitative RT-PCR was carried out using the ABI
Prism 7000 sequence detection system (Applied Biosys-
tems, (Foster City, CA, USA). All samples were run in
triplicate in 96-well plates. The quantitative RT-PCR re-
action was carried out using 6 μl SYBR® Green Dye (Ap-
plied Biosystems), 3 μl of 30-times diluted cDNA and 3 μl
of a mix containing both the forward and the reverse
primers (see Additional file 2), and incubated under the
following conditions: 2 minutes at 50 °C, 10 minutes at 95
°C, followed by 40 cycles of 15 s at 95 °C and 60 °C for 1
minute. GAPDH, HPRT, and RN18S1 were used as refer-
ence genes. Relative expression levels of each gene were
analyzed using the 7300 System SDS Software (Applied
Biosystems) with the 2-ΔΔCt method [35]. The data areshown as mean 2-ΔΔCt ± standard error. The experiment
was repeated using MSCs from three different donors.
Cytokine assays
MSCs (3.0 × 104/cm2) were seeded in 24-well culture
plates. After 48 hours the supernatants were collected
and the levels of transforming growth factor (TGF)-β (Invi-
trogen), interleukin (IL)-8 (Invitrogen), vascular endothelial
growth factor (VEGF; R&D System) and stromal cell-
derived factor (SDF)-1 alpha (R&D System Inc) were
measured by enzyme-linked immunosorbent assay kits
according to the manufacturer’s instructions.
Statistical analysis
The paired t-test for variance analysis was employed to
determine the significance level of the differences found
between pre- and postoperative HHS values. Nonpara-
metric tests were used as the statistical method for
in vitro experimental data because most of the variables
were small numbers. Correlation coefficients between
clinical assessment results and cell factors were deter-
mined by means of the Spearman’s correlation test. The
results are expressed as the mean values ± standard de-
viation. All statistical analyses were performed using
GraphPad Prism software (Version 6.0; GraphPad Software,
La Jolla, CA, USA). A value of P < 0.05 was considered
significant.
Results
Improved clinical outcome of femoral heads treated with
BMMCs at early stages of osteonecrosis in sickle cell
disease
In the present study, we followed-up 89 SCD patients
with ONFH. Our study was limited to autografts of
BMMCs for patients with pre-collapse osteonecrosis of
the femoral head (Ficat stage 0, I or II). The mean length
of follow-up was 37.3 months (range 12 to 60 months).
No complications such as fracture, dislocation, nerve or
muscle lesions, clinically significant thromboembolism
or hematoma were observed during or after the treat-
ment. No patient has required further surgery.
The preoperative HHS for the cohort was 75.7 points,
and the mean score at the most recent follow-up was
93.1 points, indicating a significant difference before and
after operation (P = 0.0005) (Fig. 1a). Our procedure
achieved a significant increase in the average HHS for
the entire group of patients with pre-collapse stages of
the disease, as compared to HHS before treatment
(Fig. 1b-e). Over the 60-month follow-up period, the
mean HHS improved from preoperative 77.9 points
(range 66–86 points) to postoperative 94.0 points (range
90–98 points) for femoral heads with Ficat stage 0 (P =
0.0009, 95 % confidence interval; Fig. 1b). For those with
Ficat stage I, mean HSS improved from preoperative
Fig. 1 BMMC treatment significantly improved the outcome of femoral heads at early-stage ONFH in SCD. a–e Changes in HHS for femoral heads
grouped according to Ficat stage over the entire postoperative period. Floating bars represent maximum and minimum range of variation, with
lines at mean HHS. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, versus preoperative HHS values
Table 1 Stratified Harris Hip Score before and after implantation
of bone marrow-derived mononuclear cells
Mean Harris Hip Score (mean and range)
Ficat and Arlet stage
(n = patients)
Preoperative Final follow-up P value
Stage 0 (n = 20) 77.9 (66–86) 94.0 (90–98) 0.0009
Stage I (n = 31) 76.3 (68–87) 96.8 (94–100) 0.0003
Stage IIA (n = 16) 71.8 (64–88) 92.0 (90–96) 0.028
Stage IIB (n = 22) 70.9 (54–88) 89.6 (84–92) 0.013
Total (n = 89) 75.7 (54–92) 93.1 (88–100) 0.0005
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points (range 94–100 points) (P = 0.0003, 95 % confi-
dence interval; Fig. 1c). For femoral heads with Ficat
stage IIA, mean HSS improved from preoperative 71.8
points (range 64–88 points) to postoperative 92 points
(range 90–96 points) (P = 0.028, 95 % confidence inter-
val; Fig. 1d). For femoral heads with Ficat stage IIB,
mean HSS improved from preoperative 70.9 points
(range 54–88 points) to postoperative 89.6 points (range
84–92 points) (P = 0.013, 95 % confidence interval;
Fig. 1e). The mean HHS before and after implantation of
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ferences indicated the beneficial effect of BMMC infu-
sion on the recovery of hip function, reduced pain, and
higher quality of daily activities of the patients.
Forty-five days after the procedure, 60 patients re-
ported no pain and 26 patients reported moderate pain,
which disappeared by 90 to 100 days. Considering clin-
ical improvement in pain, only 3.7 % (3 out of 89) of
the treated patients did not reach a satisfactory clinical
result. Two of 16 patients with a femoral head with
Ficat stage IIA reported no decrease in pain at 10 to 12
months after surgery. One of 16 patients with a femoral
head at Ficat stage IIA reported progressive and severe
hip pain at 18 months. However, at X-ray examination
the disease stage of these femoral heads remained un-
changed. During the follow-up period, the patients
showed no radiographic progression of the disease.
Radiographic outcome
Preoperative and postoperative X-ray evaluations of pa-
tients indicated that the radiographic aspects were less
significant than the clinical evaluation results. Antero-
posterior X-ray projections of hips whose clinical pro-
gress was favorable did not show any evolution to sub-
chondral fracture in the weight-bearing area (curvilinear
subchondral radiolucent line) or disease progression,
with no patent enlargement of the lesion size. Postopera-
tive MRI scans demonstrated changes in lesion size and
signals due to reduction of bone-marrow edema sur-
rounding the necrotic lesion. Most lesions that appeared
stable on MRI were clinically also stable or improved.
Radiographic images from a representative successful
case of a SCD patient with stage IIB osteonecrosis of the
femoral head, successfully treated with BMMC implant-
ation at 60-month follow-up period, are shown in Fig. 2.
Grafted BMMCs enriched in connective and osteogenic
progenitor cells
An average of 120 ± 10 mL of bone marrow harvest from
the iliac crest was concentrated into 40 ± 8 mL within 90
minutes after density centrifugation with Ficoll. The num-
ber of mononuclear cells increased from 8.9 ± 2.6 × 106
cells/mL in the initial BMA to 24.3 ± 9.1 × 106 cells/mL
after concentration (Fig. 3a). After 10 days in culture, an
average of 28.2 ± 13.9 CFU-F colonies was observed in
BMMC (1.0 × 106 cells/25 cm2) cultures (Fig. 3b, c, f) com-
pared to 8.4 ± 5.3 colonies (1.0 × 106 cells/25 cm2) in the
BMA group (see Additional file 3). A final volume of 40
mL concentrated BMMC suspension was injected into the
femoral head; hence, we have administered an average of
9.7 ± 3.6 × 108 BMMCs to each femoral head with ONFH
which contained about 2.7 ± 1.4 × 104/cells of CFU-F.
After 21 days under osteogenic medium cultivation,
bone nodules were detected with Alizarin Red stain,indicating the presence of osteoprogenitor cells (CFU-O)
in BMMC (Fig. 3d–f ). The frequency of CFU-O repre-
sented approximately 40 % of CFU-F (Fig. 3f) demonstrat-
ing that our technique isolates and concentrates a
heterogeneous mixture of mononuclear cell populations
especially rich in connective tissue and osteogenic stem
cells. Of importance for their clinical utility, the total
amount of CFU-F and morphological findings were not
statistically different among the group of SCD patients
with pre-collapse ONFH (Fig. 3g). Moreover, these results
demonstrate that the grafted BMMC contained viable pro-
genitor cells even when the injection was performed 1
hour after the initial aspiration, during our surgical
technique.
Endothelial progenitor/hematopoietic stem cell
phenotype frequencies are increased in grafted BMMCs
In order to further characterize the heterogeneous group
of the BMMC population, the phenotype of BMA and
BMMC was analyzed for the surface markers: CD34,
CD133, KDR (VEGFR2), CD45 and their appropriate
isotype-matched IgGs. EPCs were predefined as cells ex-
pressing a combination of surface markers CD34+CD133
+KDR+, to indicate that they belong to the bone marrow
early progenitors (CD34+), their immaturity (CD133+) and
endothelial origin (KDR+). Conversely, another subset of
CD45dim cells indicated immaturity/hematopoietic origin,
marking the phenotype CD34+CD45dimKDR+ as a differ-
ent subpopulation of EPC.
There were significantly lower quantities of CD34+CD133+
KDR+ (P < 0.01) and CD34+CD45dimKDR+ (P < 0.01) in
BMA as compared to in BMMCs, showing that fresh EPC
were enriched in the grafted BMMCs (Fig. 4a–d). In
addition to the EPC phenotype, we also found CD34+/
CD45dim (P < 0.007) to be significantly different between
BMA and BMMCs. The average concentration of BMMCs
compared to the initial BMA was 2.8 ± 1.4-fold for
CD34+KDR+, CD34+CD133+KDR+, CD34+CD45dim and
3.2 ± 1.5-fold for CD34 + CD45dimKDR+ (Fig. 4e).
Overall, EPC identifying markers (CD34, KDR, CD133
and CD45dim) were significantly enriched after separation
on BMMCs as compared to the fresh BMA samples. The
numbers of cell phenotypes for various marker combina-
tions are shown in Table 2.
Multipotent mesenchymal stem cell phenotype is present
in BMMCs from sickle cell disease patients
Previous studies have described that the differentiation
potential, proliferation rate and MSC content in BMMCs
were variable in patients with non-traumatic osteonecro-
sis [19–21], suggesting that the effectiveness of cell ther-
apy may be related to the availability of MSCs according
to the risk factor. In view of a paucity of information re-
garding MSCs in SCD, we decided to investigate the
Fig. 2 Radiographic sequence from a representative case of a symptomatic 44-year-old man with ONFH successfully treated with BMMC implantation.
a Coronal T1-weighted MRI scans of the right hip before surgery show osteonecrotic lesion in Ficat IIB stage. The osteonecrotic lesion is
surrounded by sclerotic low-signal margin (arrow) with subjacent marrow edema. b Anteroposterior X-ray radiograph showing minimally
invasive decompression. The trephine was introduced under fluoroscopy through the greater trochanter into the femoral head. The BMMCs
were injected through the trephine into the necrotic zone. c, d Twelve-month postoperative coronal (c) and axial (d) MRI (T1-weighted) scans
after autologous BMMC implantation showing the channel, decreased bone edema and changes of signal in the superior part of the femur.
Axial MR image (d) shows well-delimited marrow region of increased signal intensity (arrow) within the necrotic area and hypointense line
around them due to reparative new bone. e, f Preoperative (e) and 60-month postoperative anteroposterior (f) radiographs of the same hip
showing the femoral head has maintained the sphericity (arrow)
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collapse osteonecrosis. First, we selected age-matched
and Ficat stage-matched BMMC samples to isolate MSC
populations. The expansion kinetics curves and the mor-
phological characteristics of ex vivo MSCs were not sta-
tistically different among SCD patients with pre-
collapsed ONFH. Expanded MSC from SCD patients
formed a homogenous monolayer of adherent spindle
shaped fibroblast-like cells (Fig. 5a, b). The isolation
protocol proved to be successful in all the BMMC col-
lections, and sufficient numbers of MSCs were obtained
after 4 weeks. After the third passage, we observed for
each culture that isolated cells were negative for typical
hematopoietic or endothelial antigens CD45, CD34,
CD133 and CD31, and were positive for mesenchymalcell surface markers CD29, CD90, CD105, CD146
(Fig. 5f ). Expanded MSC populations at low passages
(third to sixth) showed a similar expression pattern of
surface markers. In addition, there was no significant
variation of surface marker expression in MSC cultures
from different hemoglobin genotype or disease stage
samples (see Additional file 4).
Osteogenic potential of MSCs is not defective in sickle
cell disease patients with osteonecrosis
The differentiation of MSCs from SCD patients into adi-
pogenic, osteogenic and chondrogenic phenotypes was
monitored using specific staining as previously described.
All MSC cultures showed the capacity to differentiate
along the three lineages tested (Fig. 5c–e). After
Fig. 3 Increased number of conjunctive and osteogenic progenitor cells in concentrated BMMC. a Scatter plots showing the distribution of total
mononuclear cell number in 1 × 106 cells/mL after bone marrow aspiration (BMA) and after concentration of bone marrow-derived mononuclear
cells (BMMC) on Ficoll density gradient centrifugation. b, c Flask and morphologic characteristics of colony-forming unit-fibroblasts (CFU-F) from
BMMC. d, e Flask with mineralized matrix stained with red Alizarin-S and Crystal Violet of colony-forming unit-osteoblasts (CFU-O) from BMMC. f
Frequency of CFU-F/106 cells and CFU-O/106 cells in concentrated BMMC. g Frequency of CFU-F/106 cells isolated in BMMC from individuals with
osteonecrosis at a distant site was independent of the disease stage. The high standard deviation indicates the high variability of CFU-F and
CFU-O within the SCD bone marrow. Data are represented as individuals values. Horizontal bars indicate mean value. Scale bar: 50 μm.
***P < 0.001. NS, not significant
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the cell cytoplasm and were stained by Oil-Red-O, which
proved adipogenic differentiation in MSC expanded sam-
ples (Fig. 5c). After the induction of chondrogenesis, the
samples were positively stained for acid mucopolysaccha-
rides by Alcian blue (Fig. 5e). After osteogenic induction,
cell shape flattened and broadened (Fig. 5d). Osteogenic
differentiation was associated with calcium deposit forma-
tion, and staining by Alizarin Red S was found in all MSC
samples. The differentiation potential of MSCs was main-
tained up to 6 passages. These in vitro differentiation as-
says confirmed the multipotent potential of MSCs present
in BMMC from SCD patients.
The immunocytochemical staining results for osteo-
genic induction were confirmed by quantitative PCR.
Osteoblast lineage-specific markers (RUNX2, ALPL and
COL1) are expressed during in vitro osteodifferentiation
of MSCs and precede the late-stage mineralization
process [36, 37]. After 10 days of differentiation, signifi-
cantly higher expression levels of osteogenic specific
genes RUNX2, ALPL and COL1 were observed in MSCs
cultured under osteogenic medium, as compared withcontrol MSC samples from at least five SCD patients
(Fig. 6a). Quantitative PCR analysis showed that mRNA
fold-changes of the osteogenic genes were highly similar
in differentiated MSCs, with the exception of ENG
mRNA expression levels, which were similar between
control and osteogenic-induced samples (Fig. 6a). Ex-
pressions of genes specific for osteogenesis were not sig-
nificantly different between samples from HbSS and
HbSC. Osteocalcin, a marker of developing osteoblasts,
was detected at higher levels in osteogenic-induced
MSCs compared to control MSCs after 10 days (Fig. 6b).
The upregulation of osteogenesis-specific genes had
already started after 10 days of differentiation, although
no calcium formation was observed at this time point.
However, after 21 days, the mean percentage of the area
stained with Alizarin Red S was 28.3 ± 10.5 % in MSCs
cultured under osteogenic medium, as compared with
control MSC samples from SCD patients with ONFH.
The amount of mineralized matrix deposited during
in vitro osteogenic differentiation was not statistically
different among MSCs of SCD patients with pre-collapse
osteonecrosis stages (Fig. 6c). These results indicated
Fig. 4 Concentrated number of endothelial and hematopoietic progenitor cell phenotypes in BMMC. a–d The frequency of cell subpopulations
was obtained after labeling of total bone marrow-derived mononuclear cells (BMMC) (1 × 106 cells) separately with antibodies (set 1 CD133/
CD34/KDR or set 2 CD34/KDR/CD45) and analysis by flow cytometry. Phenotypes CD34+/KDR+ (a), CD34+/KDR+/CD133+ (b), CD34/CD45dim (c)
and CD34+/KDR+/CD45dim (d) were concentrated in the implanted BMMC of SCD patients. e Concentration factor calculated by the quotient of
the specified phenotype number in BMMC/BMA. The high standard deviation indicates the high variability of cell phenotypes within the SCD
bone marrow. Data are represented as individuals values. Horizontal bars indicate mean value. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
BMA bone marrow aspirate
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the ability of osteogenic differentiation after population
expansion in our culture conditions.
The observation that MSC populations can be ex-
panded from SCD patients with osteonecrosis and canreadily be induced to an osteogenic phenotype does not
exclude the possibility that they may also produce and
secrete amounts of growth factors and cytokines that
mediate endogenous bone regeneration. Therefore, we
analyzed the protein levels of IL-8, TGF-β, SDF-1α and
Table 2 Endothelial progenitor cell phenotype and different
progenitors are enriched in bone marrow-derived mononuclear
cells (number of cells/mL ± SD)
Cell phenotype BMA (n = 20) BMMC (n = 10) P value
CD34+CD133+ 587.9 ± 239.4 756.9 ± 269.0 0.667
CD34+KDR+ 341.0 ± 103.5 954,9 ± 251.7 0.012
CD34+CD133+KDR+ 239.6 ± 75.75 744.9 ± 226.7 0.010
CD34+CD45dim 342.9 ± 85.17 947.4 ± 261.7 0.007
CD34+CD45dimKDR+ 166.2 ± 53.04 517.8 ± 157.0 0.013
BMA bone marrow aspirate; BMMC bone marrow-derived mononuclear cells
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these proteins are known to be intimately involved in
the regulation of bone metabolism. We found that MSCs
grown under control conditions secreted significant
amounts of IL-8, TGF-β and SDF-1α, although with dif-
ferent levels (Fig. 6d). Cell culture medium without cells
or serum was used as the negative control. Based on the
observation that osteogenic differentiation of MSCs was
not hampered under our culture conditions, we ques-
tioned whether MSCs secreted factors that might im-
prove vascularization of the necrotic area in a clinical
setting. We analyzed the concentrations of VEGF in the
supernatant of MSCs. We observed an accumulation of
minor amounts of VEGF under control conditions over
48 hours. This indicates that MSCs from SCD patients
are capable of producing vasculogenic cytokines and
growth factors that might mediate endogenous bone
regeneration.
Discussion
The present study was the first 5-year clinical trial in
Brazil addressing cell therapy of avascular osteonecrosis
of the femoral head in sickle cell-ill patients. The current
study demonstrated that pre-collapse stages of ONFH in
SCD patients could be treated safely and efficiently with
BMMCs enriched with stem/progenitor cells combined
with minimally invasive decompression. The implant-
ation of BMMCs significantly decreased hip pain and
other joint symptoms, and prevented the progression of
the disease towards later osteonecrotic stages or collapse
of the femoral head in SCD patients.
In this study, we conducted a 60-month follow-up on
the patients, since disease progression and collapse of
the femoral head are usually found in this period [38].
The major study limitation is the fact that no control
group with decompression alone or with conservative
treatment was included. The current data were com-
pared with the natural evolution of hip osteonecrosis in
adults with SCD [30]. In fact, even the 3.4 % (3 out of
89) of the treated patients that did not achieve the ex-
pected satisfactory clinical result were markedly better
than those left to the natural evolution of ONFH.Extensive reports have described that, without a specific
intervention, 70 % to 90 % of clinically diagnosed ONFH
cases in SCD patients will progress to collapse of the
femoral head and to secondary osteoarthritis within a
5-year period, and they will consequently undergo
arthroplasty [6, 7]. In a series of 75 symptomatic SCD
hips with ONFH, Hernigou et al. [38] described that
disease progression occurred regardless of the stage at
the initial diagnosis or in the presence/absence of sig-
nificant risk factors that could cause collapse, suggest-
ing that conservative treatment procedures should be
instituted early to prevent a poor outcome in this dis-
ease. In our study, sickle-ill patients with early-stage
ONFH (Ficat stage 0 to IIB) were enrolled for treat-
ment when necrosis does not yet involve the complete
femoral head. Patients with Ficat stage 0/I showed sig-
nificant improvement in pain and function, and none
of them progressed clinically. Among patients with
stage IIA/IIB, 35 hips (out of 38) were treated success-
fully, while the rest reported no change or progressive
pain. Importantly, we found that all patients who were
treated with decompression and implantation of
BMMCs enriched with stem/progenitor cells did not
show postoperative collapse of the femoral head during
the 60-month follow-up. Our results indicate a reduc-
tion in pain severity and other joint symptoms associ-
ated with early stages of ONFH with this treatment,
and, at least for the 60-month follow-up period, dis-
ease progression remained stable.
The prevalence of osteonecrosis in patients with SCD
is high, reaching up to 50 % of these individuals by 35
years of age, and their occupational and physical activity
is substantially limited [6, 38, 39]. Several strategies have
been examined to preserve rather than replace the fem-
oral head and articular cartilage in SCD patients with
osteonecrosis.
In our study, implantation of BMMC concentrate with
minimally invasive decompression was used for all pa-
tients. Decompression with small-diameter 3-mm tre-
phine had to be used to avoid leakage of the implanted
BMMC population. This technique was developed to be
less invasive and to reduce the risk of cartilage damage
[40].
Avascular ONFH in SCD patients is a condition that
progresses slowly, and for which no effective therapeutic
option currently exists. Early in the course of the dis-
ease, core decompression remains the most logical treat-
ment modality if one accepts that the condition is a
compartment syndrome [40]. In an updated systematic
review, Martí-Carvajal et al. [41] identified only one ran-
domized prospective clinical study for osteonecrosis re-
lated to SCD. The report failed to show that core
decompression alone or combined with physical therapy
halted disease progression, improved clinical symptoms
Fig. 5 (See legend on next page.)
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Fig. 5 Expansion, characterization and pluripotency properties of human MSCs from SCD patients. a Ex vivo expanded mesenchymal stromal cells
(MSC) from SCD patients with pre-collapse ONFH at a distant site in control culture conditions. Total viable cell counts of MSCs from donors with
progressive disease stage are plotted for MSCs expanded in fetal bovine serum. b Morphologic characteristics of MSCs at passage 3. c–e Differentiation
of MSCs. Results of staining assays on MSCs induced to osteogenic differentiation (c, mineralized bone nodules stained with Alizarin red), adipogenic
differentiation (d, intracellular lipid droplets stained with Oil red O), and chondrogenic differentiation (e, static micromass cell culture stained with
Alcian Blue). f Immunophenotyping profile of MSCs isolated from SCD patients. Negative peaks (green line) correspond to cell autofluorescence. MSCs
were positively labeled to CD29, CD90, CD105, CD146 and negatively labeled to CD31, CD34, CD45 and CD133. Data are mean ± SD number of cells
(n = 4). Data are representative of three independent experiments. Magnification: 400× in b–d. Scale bar: 50 μm in e
Daltro et al. Stem Cell Research & Therapy  (2015) 6:110 Page 13 of 18or improved quality of life in people with SCD [42].
Thus, despite several case series describing the utility
of this procedure and its widespread use in clinical
practice, the possible beneficial effects of hip core de-
compression alone for ONFH related to SCD remain
inconsistent.
Since small-diameter decompression therapy alone
does not stop the frequent progression to subchondral
fracture of the femoral head in sickle-ill patients [42–
44], our data suggest that implantation of BMMC con-
centrate with a minimally invasive technique might be
effective in preventing the natural evolution to collapse
of ONFH and will help avoid joint replacement in SCD
patients. A recent study by Al Omran [44] compared the
efficacy of decompressive methods for the treatment of
pre-collapse ONFH in a consecutive series of SCD pa-
tients. He observed significant improvement in pain at
the end of 2 years for Ficat stage I patients, but the clin-
ical failure rate, as measured as progression to end-stage
ONFH requiring hip arthroplasty, still reached 20–50 %
in stage IIA/IIB patients. Thus, core decompression
alone can delay the natural progression to collapse in
SCD patients but still has a high failure rate without
bone marrow grafting.
A small number of clinical studies of autologous
BMMC implantation for early ONFH in SCD patients
has been carried out. The original prospective study [19]
of 189 hips treated with core decompression and autolo-
gous bone marrow concentrate has proved very benefi-
cial in identifying the procedure and the number of
injected progenitor cells needed for a better outcome.
However, the influence of etiologic factors on the out-
come was not demonstrated since the majority of ONFH
in these patients was idiopathic, alcohol induced, or ster-
oid related. Our findings are consistent with those re-
ported by Hernigou et al. [30] who found greater clinical
improvement, decreased pain, delayed progression of the
disease and no subchondral fracture of the femoral head
in sickle-ill patients treated with minimally invasive de-
compression and autologous bone marrow concentrate.
The efficacy of BMMC implantation into ONFH was re-
ported for all the patients postoperatively during a
period as long as 17 years with the longest follow-upand with an average period of 10 years for 87 % of the
hips [30].
Other studies that included pre-collapse ONFH pa-
tients, with diverse underlying pre-operative etiologies,
have reported satisfactory decreases in pain and joint
symptoms in patients treated with core decompression
and implantation of BMMCs [15, 45, 46]. However, these
studies did not prevent the evolution to the fracture
stage between 24 and 60 months of follow-up. Indeed, in
the bone marrow-grafted hip, one or more hips pro-
gressed to stage 3 during the follow-up period. In 2011,
Gangji et al. [17] in a prospective randomized controlled
trial reported that 8 of 11 hips in the core decompres-
sion group alone progressed to fracture and collapse,
while in the core decompression and BMMC group only
3 of 13 progressed to collapse at the 5-year follow-up
period. In a recent prospective trial, Ma et al. [47]
looked at a similar group of patients (53 hips) with Ficat
stage I to III ONFH. After a 2-year follow-up period
there was a significant relief in pain (P < 0.05) and clin-
ical joint symptoms in the core decompression and
BMMC treatment group compared to the core decom-
pression group alone. In addition, a significant number
of hips in the core decompression group have deterio-
rated to the next stage after 24 months post-procedure
compared to the BMMC treatment group.
Our study also showed promising biological properties
of BMMCs enriched in stem/progenitor cells to be used
for the treatment of early stages of OHFH related to
SCD. We demonstrate that ex vivo expanded MSCs
from SCD patients maintained the cell replicative cap-
acity without significant loss of their specific biomolecu-
lar characteristics, differentiation capacity into multiple
mesenchymal phenotypes, and osteogenic differentiation
activities. Furthermore, the presence of vasculogenic cy-
tokines and growth factors (IL-8, TGF-β, SDF-1α and
VEGF) in conditioned medium from MSCs reinforce the
beneficial effects for cell therapy of ONFH in SCD
patients.
The rational for a cell-based strategy for the treatment
of ONFH is to provide stem cells and other progenitor
cells to potentially improve the local environment in the
affected hip. In SCD, however, previous studies have not
Fig. 6 (See legend on next page.)
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Fig. 6 Osteogenic abilities of bone marrow-derived MSCs are not defective in patients with osteonecrosis. a Quantitative RT-PCR of osteoblast-
related genes from control and osteogenic-induced MSCs after 10 days were normalized and compared according to housekeeping genes as
control. b Scatter plots (left) showing the distribution of total fluorescence intensity from FACS analysis (right) of cellular osteocalcin expression in
MSCs. The relative fluorescence intensity shows significant differences between control and osteogenic differentiation conditions. c Alizarin Red
staining (left) indicating mineralized nodule formation of cultured MSCs after treatment with osteogenic media for 21 days. Quantitative analysis
of the amount of Alizarin staining in each group is also indicated (right). No significant difference (NS) was found between MSCs from SCD
patients with early-stage osteonecrosis and patients with further stages of the disease at a distant site. Alizarin Red staining was independent of
the disease stage. d Enzyme-linked immunosorbent assay for interleukin-8 (IL-8), transforming growth factor-beta (TGF-β), stromal cell-derived factor-
1alpha (SDF-1α) and vascular endothelial growth factor (VEGF). Concentration (pg/mL) of cytokines and growth factors in supernatants of MSCs of SCD
patients after 2 days of culture. MSCs from SCD patients produce distinct levels of IL-8. Horizontal bars represent the mean and SD of data. The
triangles represent individual values. *P < 0.05, **P < 0.01, ***P < 0.001
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populations in the infused BMMCs or have not ad-
dressed the potential of the cells isolated from SCD pa-
tients [19, 30]. In our study, we further characterized the
heterogeneous group of the bone marrow stem cell
population isolated from SCD patients with ONFH.
FACS analyses of the infused BMMCs have shown enriched
cell populations with surface markers characteristic of
endothelial progenitors and hematopoietic stem cells, as
compared to mononuclear cells in the native BMA of SCD
patients. Furthermore, the number of CFU-F and CFU-O
produced in BMMCs, which are representative of the total
number of connective progenitors, were significantly higher
as compared to native BMA. Thus, it can be assumed that
the infused BMMCs contained an enriched mixture of
MSCs and endothelial and hematopoietic progenitor cells.
The efficacy of the cell-based therapeutic approaches
to enhance tissue repair in ONFH is based on the fre-
quency and activity of MSC content in the grafted
BMMCs [12]. However, there is evidence that the repli-
cative capacity and osteogenic activity of MSCs in the
bone marrow are decreased in non-traumatic ONFH
[19–21, 23]. Hernigou and Beaujean described that the
number of both granulocyte-macrophage progenitor
cells in the hematopoietic compartment and fibroblast
colony-forming units in the stromal compartment of the
bone marrow of the iliac crest were decreased in pa-
tients who were receiving corticosteroids or who abused
alcohol [22]. In addition, a more recent comparative
analysis of the osteogenic and growth potential of MSCs
in patients with ONFH has shown differences according
to the risk factors [21]. In our study, the obtained data
demonstrate that the replicative activities, osteogenic dif-
ferentiation abilities and production of cytokines and
growth factors in MSCs isolated from the iliac crest are
not impaired in sickle cell-ill patients with early stages
of ONFH. Moreover, the ex vivo expanded MSCs main-
tained cell replicative capacity without significant loss of
their specific biomolecular characteristics and differenti-
ation potential into multiple mesenchymal phenotypes.
These findings extend the notions that MSCs from SCDpatients, either in BMMCs or ex vivo expanded in cul-
ture, represent an ideal cell type to mimic a bone auto-
graft, containing all the key components required for
bone repair in pre-collapse stages of ONFH.
We are aware that our experimental design has several
limitations. The presented data is not a controlled study,
and no parallel control groups of decompression alone
and conservative treatments were included. SCD is a
systemic life-threatening hemoglobinopathy associated
with a high prevalence of comorbidities, and SCD patients
are at more risk of intra- and post-operative complications
and suboptimal outcome of complex orthopedic proce-
dures [48–50]. The high failure rate of core decompres-
sion alone and the potential risk of harm during surgical
intervention for SCD patients allocated to a control group
predict a poor prognosis for these patients. This stands in
contrast to the safety and efficiency confirmed by a long-
term follow-up of patients receiving the cell therapy. The
inclusion of a control group was not in accordance with
the ethical recommendations of the national authorities
that have analyzed and provided the financial support for
this study. Quite clearly, prospective randomized studies
including a comparison with an active control group
would be nevertheless desirable in order to determine
more comprehensively the efficacy of the treatment de-
scribed in this study.
Another limitation is consequent to the fact that only
a few patients underwent MRI during the follow-up, and
we were unable to monitor bone formation in the necrotic
area or examine how this may have affected outcomes. Fu-
ture studies should incorporate such monitoring. We also
cannot be certain whether the grafted BMMCs remained at
the site of implantation and/or participated in mobilization
of resident or circulating mesenchymal cells into the le-
sion. The BMMC solution was completely absorbed by
the bone-filling material and the cells may have found an
autologous environment similar to the bone marrow from
which they have been obtained.
We used MSCs expanded from SCD patients with the
very early stages of ONFH (Ficat 0) as a comparison
group to MSC expanded from later stages (Ficat I, II)
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samples from SCD patients without an overt involvement
of the skeletal tissues. Most clinical studies investigating
the biological properties of MSCs have demonstrated that
the number of CFU-F in the iliac crest of control patients
without osteonecrosis is equivalent to the patients with
pre-collapse stages in ONFH secondary to SCD [11, 30].
Moreover, there is evidence that active new bone formation
occurs in femoral heads around necrotic areas in most
SCD patients with ONFH when compared to a “low-risk”
osteonecrosis cohort of patients [50, 51].
We are aware that the differentiation of MSCs is highly
dependent upon in vivo and in vitro conditions, and our
in vitro findings may not reflect the potential of MCS in
an in vivo environment. Yoo and coworkers demonstrated
that ex vivo expanded MSCs isolated from the iliac crest
of patients from idiopathic or alcohol-induced ONFH
have similar proliferative activities and osteogenic differ-
entiation abilities compared with those of patients with a
non-necrotic hip disorder [52]. Therefore, for cell-based
strategies, freshly prepared BMMCs enriched with MSCs
may better represent the in vivo condition and the data
demonstrated in BMMCs may better be related to satis-
factory clinical outcomes. However, we also consider that
interpersonal variations and potential experimental bias
are likely to increase when assays are conducted separately
using freshly prepared cells.
Our study did not allow study of the relationship be-
tween the clinical outcome and the number or phenotypic
profile of cells implanted per volume of lesion. We found
substantial donor-dependent variations and high variabil-
ity in terms of CFU-F and CFU-O within the SCD
BMMCs. Similarly, Siddappa and coworkers have noted
osteogenic variability in human BMMCs as a result of
sampling method and cellular heterogeneity among the
donor population [53]. So far, we have been unable to de-
fine which cells might be responsible for the therapeutic
effects in the mixture of stem cell populations in the
grafted BMMCs. Moreover, some of the cells might have
leaked through the trephine, although the greatest part of
the bone marrow remained in the area of osteonecrosis.
Another possible explanation for the therapeutic effect is
that injected BMMCs secreted and supplied osteogenic
and angiogenic factors resulting in increased osteogenesis
(i.e., TGF-β, IL-8) [13, 54] and angiogenesis (i.e., VEGF,
SDF-1α) that would create sufficient bone repair capacity.
Further studies must be carried out to confirm the clinical
effectiveness of this technique with a longer follow-up
time in comparison to standard surgical treatment.Conclusion
Our clinical and laboratory findings indicate that the
replicative abilities, osteogenic potentials and secretionof osteogenic/angiogenic factors by MCSs are not im-
paired in SCD patients with early stages of ONFH. They
also indicate that minimally invasive implantation of au-
tologous BMMCs enriched with progenitor/stem cells is
a promising strategy for the treatment of ONFH and
orthopedic pathologies related to SCD.
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